Regeneron beats Q2 estimates as Dupixent sales drive growth

Regeneron Pharmaceuticals Inc. reported second-quarter revenue that topped Wall Street estimates, fueled by continued growth of its blockbuster drug Dupixent.

"The strong Dupixent performance reflects sustained demand across approved indications," said Marion McCourt, Commercial Head at Regeneron, in a statement.

Revenue rose to $X.X billion in the quarter ended June 30, compared with $X.X billion a year earlier. Analysts had projected $X.X billion, according to consensus estimates compiled by Bloomberg. Adjusted earnings per share came in at $XX.XX, beating the consensus estimate of $XX.XX.

The beat extends Regeneron's streak of quarterly outperformance as Dupixent, developed jointly with Sanofi SA, continues to capture market share in atopic dermatitis, asthma, and nasal polyps. The drug generated $X.X billion in sales during the quarter, up X% year over year. Eylea, Regeneron's treatment for wet age-related macular degeneration, contributed $X.X billion, facing increased competition from Roche Holding AG's Vabysmo.

Shares of Regeneron rose X% in after-hours trading following the release. The company maintained its full-year 2026 revenue guidance, signaling confidence in the pipeline. Investors will watch the upcoming PDUFA date for the company's next regulatory catalyst.

This article is for informational purposes only and does not constitute investment advice.